GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NovaBay Pharmaceuticals Inc (AMEX:NBY) » Definitions » Tangible Book per Share
中文

NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Tangible Book per Share : $0.12 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NovaBay Pharmaceuticals Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. NovaBay Pharmaceuticals's tangible book value per share for the quarter that ended in Dec. 2023 was $0.12.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


NovaBay Pharmaceuticals Tangible Book per Share Historical Data

The historical data trend for NovaBay Pharmaceuticals's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovaBay Pharmaceuticals Tangible Book per Share Chart

NovaBay Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.22 10.32 -0.17 2.43 0.12

NovaBay Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.43 1.64 0.92 0.39 0.12

Competitive Comparison of NovaBay Pharmaceuticals's Tangible Book per Share

For the Biotechnology subindustry, NovaBay Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovaBay Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NovaBay Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NovaBay Pharmaceuticals's Price-to-Tangible-Book falls into.



NovaBay Pharmaceuticals Tangible Book per Share Calculation

NovaBay Pharmaceuticals's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3.314-1.95-0)/11.2302
=0.12

NovaBay Pharmaceuticals's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(3.314-1.95-0)/11.2302
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


NovaBay Pharmaceuticals  (AMEX:NBY) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


NovaBay Pharmaceuticals Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of NovaBay Pharmaceuticals's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NovaBay Pharmaceuticals (NovaBay Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2000 Powell Street, Suite 1150, Emeryville, CA, USA, 94608
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare and skincare products. Its leading product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is proven in laboratory testing to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available direct to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Executives
Tommy Law officer: Interim CFO 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Jeffrey Kunin officer: President, DERMAdoctor, LLC 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Audrey Kunin officer: Chief Product Officer 4346 BELGIUM BLVD NW, RIVERSIDE MO 64150
Justin Hall officer: General Counsel 5980 HORTON STREET, SUITE 550, EMERYVILLE CA 94608
Yongxiang Zheng director NO.10, UNIT 1, LIJING VILLA, TIANZHU, SHUNYI DISTRICT, BEIJING F4 101316
Julie Garlikov director 2420 17TH STREET, SUITE 220, DENVER CO 80202
Andrew D. Jones officer: CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Mijia Wu director SUITE 6C, BLDG 3, YOU YOU CENTURY PLAZA, NO 428 YANG GAO SOUTH ROAD, SHANGHAI F4 CHINA
Jian Ping Fu 10 percent owner LEVEL 1, BLDG 1, GREENWOOD BUSINESS PARK, 301 BURWOOD HWY, BURWOOD C3 3125
Wang Xu officer: NEO - Sr Mgr and Controller 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Swan Sit director 95 JACKSON STREET, NEWTON MA 02459
Yenyou Zheng director 1055 WEST HASTINGS STREET, SUITE 1980, VANCOUVER A1 V6E 2E9
Xiaopei Wang director 2/44 FRANKLIN ROAD, DONCASTER EAST C3 3109
Jason Philip Raleigh officer: Interim CFO and Treasurer 2000 POWELL STREET, SUITE 1150, EMERYVILLE CA 94608
Pioneer Pharma (hong Kong) Co Ltd 10 percent owner FLAT 2605, 26/F TRENDY CENTRE, 682 CASTLE PEAK ROAD, KOWLOON K3 000000